ABT 263 (Navitoclax) is a chemotherapy drug that is used to induce apoptosis in cervical, esophageal, leukemia, and lung cancer cells by inhibiting the anti-apoptotic proteins, Bcl-2 and Bcl-xL [35–38]. This evidence concerns the gene BCL2L1 and lung cancer.